Stay updated on Fevipiprant in COPD With Eosinophilia Clinical Trial

Sign up to get notified when there's something new on the Fevipiprant in COPD With Eosinophilia Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Fevipiprant in COPD With Eosinophilia Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent change in the webpage content.
    Difference
    0.1%
    Check dated 2024-06-13T21:10:15.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the proof-of-mechanism study of multiple oral doses of Fevipiprant (QAW039) in COPD patients with eosinophilia. This change may reflect new data or findings related to the study's primary purpose of reducing the burden of sputum eosinophilia in COPD patients.
    Difference
    0.1%
    Check dated 2024-06-06T14:19:33.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The webpage has been updated to include detailed eligibility criteria for participation in the study, specifying the health conditions and prior treatments required for inclusion. Previously, no information was provided about the participation criteria for collaborators and investigators.
    Difference
    31%
    Check dated 2024-05-22T20:59:51.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:32:29.000Z thumbnail image

Stay in the know with updates to Fevipiprant in COPD With Eosinophilia Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Fevipiprant in COPD With Eosinophilia Clinical Trial page.